Noxon

Company Overview

Snapshot

Founded in January 2023, Noxon operates with 1-10 employees. The company has secured funding across one round from one investor, NGT HealthCare II, to advance its drug development for fibrotic lung diseases.

Business overview

Noxon is a Health Tech & Life Sciences company focused on the development of novel oral drugs for fibrotic lung diseases. Its core product, 3-CP (3-cabamoyl-proxyl), is a stable organic radical from the nitroxides group, designed to leverage its unique antioxidant properties. This drug has demonstrated efficacy in reducing airway inflammation and hyper-responsiveness in animal models of allergic asthma. Noxon operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting the Healthcare & Life Sciences and Pharmaceuticals markets.

Company Intelligence Q&A

What is Noxon's primary focus?

Noxon is focused on developing a novel drug for the oral treatment of fibrotic lung diseases.

What is the key product developed by Noxon?

Noxon's key product is 3-CP (3-cabamoyl-proxyl), a stable organic radical from the nitroxides group, which possesses unique antioxidant properties.

When was Noxon founded?

Noxon was founded in January 2023.

What is the current development stage of Noxon's product?

Noxon's product, 3-CP, is currently in the R&D stage, as of March 2023.